• David Hable has joined Afferent (Providence, Rhode Island) as president, CEO, and a member of the company's board of directors. Hable formerly served as the worldwide president of Codman & Shurtleff, a division of Johnson & Johnson, and as president and CEO of BrainsGate. Afferent is an early-stage medical device company focused on treating chronic neurologic dysfunction.

• AmeriPath (Palm Beach Gardens, Florida), a national provider of anatomic pathology, dermatopathology, and molecular diagnostics services to physicians, hospitals, clinical laboratories, and surgery centers, appointed Dr. Michael Robles director of gastrointestinal pathology, AmeriPath North Texas. Prior to his appointment, Robles had served as a Robert E. Petras fellow at AmeriPath's Institute of Gastrointestinal Pathology and Digestive Disease.

• Eric Fung, MD, PhD, has been promoted to chief scientific officer of Ciphergen Biosystems (Fremont, California). In addition, he will chair the newly formed scientific advisory board. Fung joined Ciphergen in 2000, most recently serving as vice president of clinical and medical affairs. Ciphergen makes a family of ProteinChip Systems and services for clinical, research and process proteomics applications.

• Daxor (New York) has appointed Everis Engstrom to succeed Ron Baldry as vice president of engineering. Baldry has worked for Daxor since 1985 and will continue as a consultant in R&D. Engstrom joins Daxor with more than 25 years of experience in the medical device industry, including various roles with Beckman Coulter and Bayer Diagnostics. Daxor manufactures the BVA-100, a semi-automated blood volume analyzer, used in conjunction with a single-use diagnostic kit.